Owing to the involvement of multiple lymph node regions and the presence of systemic symptoms, the patient was diagnosed with multicentric Castleman disease and was started on steroid therapy, as well as anti-interleukin-6 (anti-IL-6) therapy, namely, tocilizumab, for the management of this condition. This evidence concerns the gene IL6 and Castleman disease.